[{"id":"258815b3-da9e-48e7-8a38-615cfaef4dbd","acronym":"TROPION-Lung02","url":"https://clinicaltrials.gov/study/NCT04526691","created_at":"2021-01-18T21:40:42.295Z","updated_at":"2025-02-25T14:07:50.610Z","phase":"Phase 1","brief_title":"Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)","source_id_and_acronym":"NCT04526691 - TROPION-Lung02","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2","pipe":" | ","alterations":" KRAS mutation","tags":["EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 04/15/2026","study_completion_date":" 04/15/2026","last_update_posted":"2025-02-19"},{"id":"065ef196-20b8-4fd5-a099-c2330533ea52","acronym":"SELECTIO-UC","url":"https://clinicaltrials.gov/study/NCT06820255","created_at":"2025-02-25T15:31:16.755Z","updated_at":"2025-02-25T15:31:16.755Z","phase":"Phase 4","brief_title":"DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.","source_id_and_acronym":"NCT06820255 - SELECTIO-UC","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" HER-2 • PD-L1 • NECTIN4 • TACSTD2","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression","tags":["HER-2 • PD-L1 • NECTIN4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 01/07/2025","start_date":" 01/07/2025","primary_txt":" Primary completion: 01/07/2026","primary_completion_date":" 01/07/2026","study_txt":" Completion: 01/07/2027","study_completion_date":" 01/07/2027","last_update_posted":"2025-02-11"},{"id":"6cdcc31a-0ce3-49ee-bdf9-1051ddeebebe","acronym":"TROPION-Lung10","url":"https://clinicaltrials.gov/study/NCT06357533","created_at":"2024-04-10T18:42:49.173Z","updated_at":"2025-02-25T16:55:47.733Z","phase":"Phase 3","brief_title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","source_id_and_acronym":"NCT06357533 - TROPION-Lung10","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1 • TACSTD2","pipe":" | ","alterations":" TROP2 positive","tags":["PD-L1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TROP2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 04/11/2024","start_date":" 04/11/2024","primary_txt":" Primary completion: 04/24/2028","primary_completion_date":" 04/24/2028","study_txt":" Completion: 05/24/2030","study_completion_date":" 05/24/2030","last_update_posted":"2025-02-04"},{"id":"2556a800-12ac-4ffc-b124-64c3995bab28","acronym":"AVANZAR","url":"https://clinicaltrials.gov/study/NCT05687266","created_at":"2023-01-18T15:59:54.978Z","updated_at":"2025-02-25T17:31:49.301Z","phase":"Phase 3","brief_title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","source_id_and_acronym":"NCT05687266 - AVANZAR","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • BRAF • ALK • ROS1 • TACSTD2","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • BRAF • ALK • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1350","initiation":"Initiation: 12/29/2022","start_date":" 12/29/2022","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-01-30"},{"id":"295e5020-e8e6-44a7-b2f8-2b091bd8b724","acronym":"","url":"https://clinicaltrials.gov/study/NCT06188468","created_at":"2025-02-26T09:08:23.112Z","updated_at":"2025-02-26T09:08:23.112Z","phase":"","brief_title":"ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors","source_id_and_acronym":"NCT06188468","lead_sponsor":"The First Affiliated Hospital of Xiamen University","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-12-18"},{"id":"73f525e9-88d1-49d4-a2a6-9faf82456aae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05262491","created_at":"2022-11-08T18:28:24.724Z","updated_at":"2025-02-25T15:35:30.552Z","phase":"Phase 1","brief_title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor","source_id_and_acronym":"NCT05262491","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab brengitecan (BL-B01D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 02/14/2022","start_date":" 02/14/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-18"},{"id":"ef68472b-7dd2-408d-a78b-45ffa120bc34","acronym":"Tropion-Lung08","url":"https://clinicaltrials.gov/study/NCT05215340","created_at":"2022-02-05T18:27:45.512Z","updated_at":"2025-02-25T15:00:14.693Z","phase":"Phase 3","brief_title":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations","source_id_and_acronym":"NCT05215340 - Tropion-Lung08","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • TACSTD2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 740","initiation":"Initiation: 03/04/2022","start_date":" 03/04/2022","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-12-13"},{"id":"d794956d-7d72-4864-b172-3cc363bc86b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06649331","created_at":"2025-02-26T09:16:39.825Z","updated_at":"2025-02-26T09:16:39.825Z","phase":"Phase 2","brief_title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","source_id_and_acronym":"NCT06649331","lead_sponsor":"Fudan University","biomarkers":" HER-2 • NECTIN4 • TACSTD2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • NECTIN4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • ruzaltatug rezetecan (SHR-A2009) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 10/21/2024","start_date":" 10/21/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-12-10"},{"id":"6ab12bae-6540-4fa6-af1d-909e42743c11","acronym":"","url":"https://clinicaltrials.gov/study/NCT06715826","created_at":"2025-02-26T10:35:26.335Z","updated_at":"2025-02-26T10:35:26.335Z","phase":"","brief_title":"Target-specific immunoPET Imaging of Breast Cancer","source_id_and_acronym":"NCT06715826","lead_sponsor":"RenJi Hospital","biomarkers":" HER-2 • TACSTD2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/21/2024","start_date":" 09/21/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-12-04"},{"id":"42d26ae2-8942-49de-8365-e5af5c762265","acronym":"NIR-II","url":"https://clinicaltrials.gov/study/NCT06713681","created_at":"2025-02-26T10:41:42.184Z","updated_at":"2025-02-26T10:41:42.184Z","phase":"","brief_title":"Trop2-targeting NIR-II Molecular Probe for Breast Cancer Precise Surgery","source_id_and_acronym":"NCT06713681 - NIR-II","lead_sponsor":"Yunnan Cancer Hospital","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/13/2024","start_date":" 05/13/2024","primary_txt":" Primary completion: 05/13/2025","primary_completion_date":" 05/13/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-12-03"},{"id":"84d273e3-f912-4f66-80af-054c9469875c","acronym":"TROPION-PanTumor01","url":"https://clinicaltrials.gov/study/NCT03401385","created_at":"2021-01-18T16:47:07.204Z","updated_at":"2025-02-25T14:58:37.689Z","phase":"Phase 1","brief_title":"First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)","source_id_and_acronym":"NCT03401385 - TROPION-PanTumor01","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" HER-2 • ER • PGR • ERBB3 • CD4 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HER-2 expression","tags":["HER-2 • ER • PGR • ERBB3 • CD4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 890","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-12-03"},{"id":"b0b8fd2c-45d2-439d-baa9-7ef0bc159fed","acronym":"TROPION-Lung07","url":"https://clinicaltrials.gov/study/NCT05555732","created_at":"2022-09-27T14:04:32.746Z","updated_at":"2025-02-25T15:00:38.318Z","phase":"Phase 3","brief_title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","source_id_and_acronym":"NCT05555732 - TROPION-Lung07","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • BRAF • ALK • RET • ROS1 • TACSTD2","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • BRAF • ALK • RET • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 1170","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-11-12"},{"id":"de32242c-e2ef-4e4e-af03-36f807029c84","acronym":"KL264-01","url":"https://clinicaltrials.gov/study/NCT04152499","created_at":"2021-01-18T20:16:04.885Z","updated_at":"2025-02-25T16:25:32.908Z","phase":"Phase 1/2","brief_title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies","source_id_and_acronym":"NCT04152499 - KL264-01","lead_sponsor":"Klus Pharma Inc.","biomarkers":" EGFR • HER-2 • MSI • BRCA • TACSTD2","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation","tags":["EGFR • HER-2 • MSI • BRCA • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 1300","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 07/16/2026","study_completion_date":" 07/16/2026","last_update_posted":"2024-06-24"},{"id":"a25e458f-d456-4e85-a09a-31d6b33ba2ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT06203574","created_at":"2025-02-27T08:36:07.217Z","updated_at":"2025-02-27T08:36:07.217Z","phase":"","brief_title":"Clinical Study of TROP-2 PET/CT for Noninvasive Diagnosis of Solid Tumors","source_id_and_acronym":"NCT06203574","lead_sponsor":"Huashan Hospital","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-18"},{"id":"9a54d64d-2889-431d-bba8-38823f83de86","acronym":"","url":"https://clinicaltrials.gov/study/NCT05922930","created_at":"2023-06-28T14:08:31.873Z","updated_at":"2024-07-02T16:34:25.851Z","phase":"Phase 1/2","brief_title":"Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer","source_id_and_acronym":"NCT05922930","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • TACSTD2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • TROP2 expression","tags":["BRCA1 • BRCA2 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • TROP2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TROP2-CAR-NK"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-06-14"},{"id":"0efb958e-6db6-4f88-833c-4fd2bb0bae83","acronym":"","url":"https://clinicaltrials.gov/study/NCT04251416","created_at":"2024-01-27T07:17:51.583Z","updated_at":"2024-07-02T16:35:01.080Z","phase":"Phase 2","brief_title":"A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma","source_id_and_acronym":"NCT04251416","lead_sponsor":"Yale University","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-05-24"},{"id":"ac428d9a-273b-4d56-88c0-0d08a880a183","acronym":"TUXEDO-3","url":"https://clinicaltrials.gov/study/NCT05865990","created_at":"2024-01-16T19:18:52.062Z","updated_at":"2024-07-02T16:35:03.380Z","phase":"Phase 2","brief_title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","source_id_and_acronym":"NCT05865990 - TUXEDO-3","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR • ERBB3 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR • ERBB3 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/24/2023","start_date":" 11/24/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-16"},{"id":"60313aae-39d1-46f7-a0a5-579cc55ccca0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06065371","created_at":"2024-01-27T07:17:56.404Z","updated_at":"2024-07-02T16:35:08.718Z","phase":"Phase 1","brief_title":"Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy","source_id_and_acronym":"NCT06065371","lead_sponsor":"Henry Ford Health System","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-19"},{"id":"8f022a9d-6b6c-47b3-b42e-3770069b52cd","acronym":"TROPION-PanTumor02","url":"https://clinicaltrials.gov/study/NCT05460273","created_at":"2022-07-15T16:05:32.169Z","updated_at":"2024-07-02T16:35:09.058Z","phase":"Phase 1/2","brief_title":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","source_id_and_acronym":"NCT05460273 - TROPION-PanTumor02","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • HER-2 • ALK • PGR • ROS1 • TACSTD2","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • PGR negative","tags":["EGFR • HER-2 • ALK • PGR • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 07/11/2022","start_date":" 07/11/2022","primary_txt":" Primary completion: 11/07/2023","primary_completion_date":" 11/07/2023","study_txt":" Completion: 05/06/2024","study_completion_date":" 05/06/2024","last_update_posted":"2024-04-17"},{"id":"568aa24d-5085-42bb-9566-eac679a7d04c","acronym":"SG-ESCC","url":"https://clinicaltrials.gov/study/NCT06329869","created_at":"2024-03-26T16:39:49.582Z","updated_at":"2024-07-02T16:35:12.799Z","phase":"Phase 2","brief_title":"Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT06329869 - SG-ESCC","lead_sponsor":"National Taiwan University Hospital","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-03-26"},{"id":"3914247b-96ea-451f-8ee1-b8dc8967ecc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066424","created_at":"2023-10-04T15:10:44.941Z","updated_at":"2024-07-02T16:35:18.780Z","phase":"Phase 1","brief_title":"Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)","source_id_and_acronym":"NCT06066424","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • HER-2 • PD-L1 • BRAF • ALK • ROS1 • NTRK • TACSTD2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression","tags":["EGFR • HER-2 • PD-L1 • BRAF • ALK • ROS1 • NTRK • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • HR positive • HER-2 negative • BRAF V600 • TROP2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/24/2023","start_date":" 10/24/2023","primary_txt":" Primary completion: 04/30/2038","primary_completion_date":" 04/30/2038","study_txt":" Completion: 04/30/2040","study_completion_date":" 04/30/2040","last_update_posted":"2024-02-19"},{"id":"735c4cb6-c266-4b82-980b-643443a3b6c5","acronym":"SETHY","url":"https://clinicaltrials.gov/study/NCT06235216","created_at":"2024-02-01T00:20:51.908Z","updated_at":"2024-07-02T16:35:21.472Z","phase":"Phase 2","brief_title":"Sacituzumab govitEcan in THYroid Cancers","source_id_and_acronym":"NCT06235216 - SETHY","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-01-31"},{"id":"8f458f5b-a65b-4a9d-a4fe-d37b5757cf52","acronym":"","url":"https://clinicaltrials.gov/study/NCT05385692","created_at":"2022-05-23T16:54:12.003Z","updated_at":"2024-07-02T16:35:21.578Z","phase":"Phase 1","brief_title":"A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors","source_id_and_acronym":"NCT05385692","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BL-M02D1"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-01-31"},{"id":"34784849-bd53-4fa3-93bd-7d5283db1211","acronym":"NIR","url":"https://clinicaltrials.gov/study/NCT05708144","created_at":"2024-01-27T07:17:55.352Z","updated_at":"2024-07-02T16:35:24.800Z","phase":"","brief_title":"NIR Fluorescent Molecular Probe for the Identification of Breast Tissue","source_id_and_acronym":"NCT05708144 - NIR","lead_sponsor":"Xiang'an Hospital of Xiamen University","biomarkers":" TACSTD2","pipe":" | ","alterations":" TROP2 positive","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TROP2 positive"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 02/17/2023","start_date":" 02/17/2023","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2024-01-01"}]